<DOC>
	<DOC>NCT00370591</DOC>
	<brief_summary>Comparison of two asthma treatments by lung function measures.</brief_summary>
	<brief_title>Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.</brief_title>
	<detailed_description>Single centre, randomised, double-blind, comparator study to demonstrate superiority of salmeterol/fluticasone propionate combination product 50/100mcg bd over fluticasone propionate 100mcg bd with respect to improvements in airway physiology (sRAW) in adults with persistent asthma treated for 4 weeks.</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion: Physician documented diagnosis of asthma which has been present for at least 6 months. Receiving a total daily dose of 200500mcg/day beclomethasone dipropionate or equivalent for at least 4 weeks prior to the start of the runin period. Exclusion: Has had 3 or more courses of oral corticosteroids in the 12 months previous to visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Inhaled corticosteroids</keyword>
	<keyword>Asthma</keyword>
</DOC>